source
- EU regulator withdraws Amgen's Tavneos authorization over serious trial breachesEuropean regulators have withdrawn the marketing authorization for Amgen's rare disease drug Tavneos, citing serious breaches in the pivotal clinical trial. The EMA said study staff from ChemoCent…
- Bankrupt Sangamo sells Fabry gene therapy to PTC and prion program to Lilly for $161MSangamo Therapeutics, currently in Chapter 11 bankruptcy, has agreed to divest its Fabry disease gene therapy and several other platforms to raise cash for the restructuring. PTC Therapeutics emer…